Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
And two speakers told a packed ballroom that their studies' results were ‘practice-changing’.
The studies were NSABP-B31 and NCCTG-N9831, parallel clinical trials investigating the use of paclitaxel and trastuzumab following anthracyclinebased chemotherapy for adjuvant treatment of high-risk HER-2 positive breast cancer.
‘Combined results for both trials showed that trastuzumab, when given concurrently with paclitaxel following AC chemotherapy, reduced the risk of distant metastases at three years by 53%’
Combined results for both trials showed that trastuzumab, when given concurrently with paclitaxel following AC (doxorubicin-cyclophosphamide) chemotherapy, reduced the risk of distant metastases at three years by 53%.
And combined early results at a median follow-up of two years show a statistically significant survival advantage with a 33% relative reduction in the risk of death.
Commentator Dr George Sledge, professor of oncology at Indiana University, was extremely enthusiastic about the trastuzumab results.
‘To answer the question, “does adjuvant trastuzumab improve disease-free survival?”, the answer clearly is yes’, Dr Sledge said. ‘Ladies and gentlemen, biology has spoken, and we should listen.
